The Novavax vaccine arrives in Luxembourg
The Council of Government of February 25 validated the arrival of the Novavax vaccine from March 1 in Luxembourg following the recommendations issued by the Higher Council for Infectious Diseases (CSMI) on February 23.
Covid-19
The Council of Government of February 25 validated the arrival of the Novavax vaccine from March 1 in Luxembourg following the recommendations issued by the Higher Council for Infectious Diseases (CSMI) on February 23.
The offer of vaccines against covid-19 will expand with Novavax following the Council of Government on February 25.
This vaccine is based on so-called “classic” technology since it is composed of protein subunits, according to a principle used for decades for the production of vaccines such as vaccines against whooping cough, hepatitis B, or human papilloma. virus (HPV).
Conditions to be met to be eligible for a dose
The vaccine can be used for the vaccination of adults aged 18 or over, according to a primary vaccination schedule with 2 doses spaced 28 days apart.
It can be used:
- In the 3rd dose as part of a primary vaccination of immunocompromised people, people benefiting from an organ transplant and people on kidney dialysis, according to a schedule at 0, 28 and 84 days (0, 4 and 12 weeks);
- as a booster dose after a single dose of the Janssen vaccine, from 28 days after the injection;
- as a booster dose for all persons receiving a complete primary vaccination course with Novavax 3 months after the last dose;
- as a booster dose for anyone who has experienced medically significant adverse effects after primary vaccination with an mRNA or viral vector vaccine.
The use of the Novavax vaccine is authorized as part of a mix-and-match vaccination schedule, and in particular:
- in people who have started a vaccination schedule with AstraZeneca, including in people who, following a first dose of vaccine, presented with a deep thromboembolic syndrome with thrombocytopenia;
- in people who have experienced myocarditis or pericarditis, or another serious adverse effect, following administration of a 1st dose of mRNA vaccine.
- in the event of covid-19 infection during the 6 months preceding vaccination, or in the event of intercurrent infection, the administration of Novavax follows a scheme analogous to the scheme recommended by the CSMI in January 2022 for mRNA vaccines .
In the absence of data on the safety of this vaccine in pregnant women, the CSMI recommends that future mothers stick to an mRNA vaccine for the primary and booster vaccination.
How to make an appointment?
The Novavax vaccine will initially only be administered in vaccination centres. Anyone wishing to receive the Novavax vaccine as a primary or booster dose must notify the vaccination center of their choice.
Any resident or non-resident with a Luxembourg registration number and aged 18 and over has the possibility of being vaccinated with or without an appointment, in one of the three vaccination centers (provisional LuxExpo, Ettelbruck and Esch-Belval) .
The administration of booster doses in the provisional LuxExpo, Ettelbruck and Esch-Belval vaccination centers is however only possible by appointment.
follow us on Facebook, Twitter and subscribe to our 5 p.m. newsletter.